Description

Mucolik (carbocysteine) Syrup 2% 125 ml Vial

Ingredients

Active ingredient: Carbocysteine 2%

Dosage

Dosage: The usual dose for adults and children over 15 years is 2.5 ml three times a day. For children aged 5-15 years, the recommended dose is 2.5 ml twice a day.

Indications

Indications: Mucolik syrup is indicated for the treatment of respiratory conditions associated with excessive mucus secretion, such as acute and chronic bronchitis, chronic obstructive pulmonary disease (COPD), and cystic fibrosis.

Contraindications

Contraindications: Do not use Mucolik syrup if you are allergic to carbocysteine or any other ingredients in the product. Consult a healthcare provider before use if you are pregnant or breastfeeding.

Directions

Directions: Shake the bottle well before use. Use the provided measuring cup to ensure accurate dosage. It is recommended to take Mucolik syrup with meals to reduce the risk of gastrointestinal side effects.

Scientific Evidence

Carbocysteine, the active ingredient in Mucolik syrup, is a mucolytic agent that works by breaking down the structure of mucus in the respiratory tract, making it easier to cough up. Studies have shown that carbocysteine can help reduce the viscosity of mucus, improve mucus clearance, and alleviate symptoms of respiratory conditions.

Additional Information

Mucolik syrup is well-tolerated, with the most common side effects being gastrointestinal disturbances such as nausea and diarrhea. It is important to follow the recommended dosage and consult a healthcare professional if symptoms persist or worsen.

Pharmacological Effects: Carbocysteine exerts its pharmacological action by disrupting the disulfide bridges in mucoproteins, reducing the viscosity of mucus and facilitating its clearance from the respiratory tract.

Clinical Trials: Clinical trials have demonstrated the efficacy of carbocysteine in improving symptoms and quality of life in patients with chronic bronchitis and COPD. A study by Zheng et al. (2018) showed that carbocysteine treatment led to a significant reduction in sputum viscosity and frequency of exacerbations in patients with COPD.